RxDoctor Payments Data

Richard Jolly, MD

Ophthalmology · Gainesville, TXNPI 1376541169

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Alcon at 33.3% of the total. Reporting peaked in 2023 at $366 and has fallen 76.5% since, to $86 in 2025. That places this record below the midpoint for ophthalmology clinicians in TX, where the typical reported total is $1,835.

$1,173in general payments, 2019–2025

Across 57 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$390
  • NEW World Medical,inc.$149
  • Bausch & Lomb Americas Inc.$141
  • AbbVie$92
  • Biotissue Holdings Inc.$91
  • Ocular Therapeutix, Inc.$61
  • plus $248 from 9 others

What the payments were for

  • Food & beverage$1,173100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,173 in reported general payments places this provider in the 40th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas →

Medicare billing

Part B allowed, 2024
$490,203
Medicare patients
1,312
Services billed
4,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine84$50,268
LumiganBimatoprost34$15,943
Cyclosporine37$8,648
Prednisolone Acetate291$7,570
Ketorolac Tromethamine120$4,656
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$4,165
Latanoprost362$3,773
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat138$3,549
ValacyclovirValacyclovir Hcl58$2,671
ErythromycinErythromycin Base144$1,703
MoxifloxacinMoxifloxacin Hcl58$1,669
Timolol Maleate141$1,425
Doxycycline Hyclate73$1,221
Ofloxacin88$1,069
Brimonidine Tartrate107$908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$92$66,210118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Gainesville

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →